TY - JOUR T1 - Clinical Protocol to Quantify AMPA Receptors Using Novel <sup>11</sup>C-labeled PET Tracer of K2 JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 325 LP - 325 VL - 60 IS - supplement 1 AU - Yuichi Kimura AU - Takahiro Yamada AU - Mai Hatano AU - Waki Nakajima AU - Tomoyuki Miyazaki AU - Takuya Takahashi Y1 - 2019/05/01 UR - http://jnm.snmjournals.org/content/60/supplement_1/325.abstract N2 - 325Objectives: This study aims at proposing a clinical protocol to quantify AMPA receptors (AMPAR). AMPAR concerns cortical reorganization, and it is expected to be applied for various brain diseases such as epilepsy or psychological disorders. We have developed the novel PET tracer, 11C‒K-2. Its kinetics has been clarified. A reversible behavior is observed, and BPND is found to be a quantitative index to AMPAR using epileptic patients; the BPND is correlated with the amount of AMPAR directly measured using the resected brain tissues (OP‒648, EANM, Dusseldorf, 2018). In this study, a condition for a static scan to acquire SUVR is investigated. Methods: 60-min dynamic scans were conducted to 30 subjects including 10 depression, 4 epilepsy, 6 healthy control, and 10 schizophrenia cases. 10 or 15 ROIs are placed onto the dynamic data, 457 ROIs in total, and BPND is computed using Logan graphical analysis where t[asterisk] is 30 min after the administration, and white matter is applied as a reference region. Then, SUVRs are computed where the scan start is varied from 20 to 60 min. The set of SUVR is compared with the BPND. Results: The typical tissue time activity curve and the Bland-Altman plot is presented. Most BPND ranges from 0.36 to 1.39. The SUVR derived from a 10-min static scan starts from 45 or 50 min after the administration well coincides with the BPND; no significant systematic and proportional errors are detected (p &lt; 0.05), and the difference between BPND and SUVR is −0.069±0.086 (a standard deviation). Conclusions: AMPAR can be quantified via the static scan protocol. A static scan is easy to be performed, and 11C‒K-2 is promising radiotracer to quantify AMPAR clinically. Further investigations on the clinical application of K-2 to brain diseases such as epilepsy or psychiatric diseases will be conducted. ER -